الفهرس 
? INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 75 |  |  |
| | | from | 75 | | |
Abstract
The 2019 novel coronavirus (COVID-19) was first identified in Wuhan, Hubei province, China, on December 31, 2019, in association with a severe human respiratory disease. Since then, it has spread rapidly. The identified symptoms of coronavirus disease 2019 (COVID-19) are fever, dry cough, sore throat, dyspnea, fatigue, myalgia, and headache. Olfactory and gustatory dysfunctions are emerging as a new symptom. They may occur in many situations related to nerve damage, autoimmune disease, malignancy, radiotherapy, inflammation, hormone imbalance, psychologic problems, ageing, etc.
We performed a cross-sectional study to estimate the prevalence of Olfactory and Gustatory Dysfunctions (OGDs) among patients infected with novel Coronavirus Disease 2019 (COVID-19). The study enrolled 200 patients diagnosed as having COVID-19 infection confirmed by PCR.
Age ranged from 21 to 60 years with mean 32.41 years. Fifty nine percent of the studied patients aged 28 years and more, 42.5% of our patients were males and 57.5% of them were females. Our patients had positive PCR for COVID-19. Lymphopenia was present in 70.5% of them.
Regarding present history, all patients had no local diseases and 15.5% had systemic disease; 7 (3.5%) were diabetic, 6 (3%) had comorbid diabetes and cardiac disease, 13 (6.5%) had comorbid diabetes and hypertension while 5 (2.5%) patients had rheumatoid arthritis.
Olfactory and gustatory impairment were prevailed in 79% of the studied patients. There is statistically non-significant association between presence of olfactory and gustatory impairment and all of gender, age group, lymphopenia or presence of local or systemic diseases. Females, aged from <28 years, lymphopenia, and systemic diseases non-significantly increased risk by 1.02, 1.99, 1.09 and 1.13 folds respectively.